Phaseline

Targets › ALPK1

ALPK1 (Alpha-protein kinase 1): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Ophthalmology, Other, Oncology; next expected readout Nov 2026.

Serine/threonine-protein kinase that detects bacterial pathogen-associated molecular pattern metabolites (PAMPs) and initiates an innate immune response, a critical step for pathogen elimination and engagement of adaptive immunity. Specifically recognizes and binds ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-negative and some Gram-positive bacteria. (UniProt, Q96QP1)

Open in Phaseline: the race on ALPK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)DF-003
ALPK1 inhibitor
ALPK1Phase 1Healthy; ROSAHNov 2026
Pyrotech TherapeuticsPTT-936
Alpha Kinase 1 (ALPK1) activator
ALPK1Phase 1Locally Advanced or Metastatic Solid TumorsSep 2027

Conditions

Healthy (1) ROSAH (1) Locally Advanced or Metastatic Solid Tumors (1)

Modalities

small molecule (2)

Companies

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) (1) Pyrotech Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.